secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2024-10-24T23:59:59+00:00
Accession:  0001724521-24-000153
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus reports casdatifan interim data: 34% ORR in heavily pre-treated ccRCC patients
--------------------------------------------------------------------------------

- ORR 34% (11/32) in efficacy-evaluable patients at 100 mg dose; confirmed ORR 25% (8/32).
- Disease control rate 81%; median progression-free survival not reached (data cutoff Aug 30, 2024).
- Patient population heavily pre-treated: 52% had ≥3 prior lines; 61% intermediate IMDC risk.
- Grade 3 TEAEs related to casdatifan were 42% (anemia 36%, hypoxia 9%); no deaths or life-threatening events.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452124000153/0001724521-24-000153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452124000153/rcus-20241024.htm
  HTML page:      https://secwatch.observer/filing/0001724521-24-000153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer